OCT4 pseudogene 5 upregulates OCT4 expression to promote proliferation by competing with miR-145 in endometrial carcinoma

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1745-1752

  Bai, Mingzhu ^a   Yuan, Mu ^a,b   Liao, Hong ^c   Chen, Jiazhou ^a   Xie, Binying ^a   Yan, Dong ^a   Xi, Xiaowei ^a   Xu, Xianming ^a   Zhang, Zhenbo ^a   Feng, Youji ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Endometrial carcinoma; MiR 145; OCT4; OCT4 pg5; Proliferation

Indexed keywords

CYCLIN D1; MICRORNA 145; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; CCND1 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN145 MICRORNA, HUMAN; POU5F1 PROTEIN, HUMAN; RNA; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE ACTIVATION; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; OCT4 PSEUDOGENE 5 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BINDING SITE; BIOSYNTHESIS; CARCINOMA; CYTOLOGY; ENDOMETRIUM; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PSEUDOGENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

BINDING SITES; BINDING, COMPETITIVE; CARCINOMA; CELL LINE, TUMOR; CYCLIN D1; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3; PHOSPHATIDYLINOSITOL 3-KINASES; PSEUDOGENES; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 84924912274     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3763     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. NCCN Practice Guidelines in Oncology. Uterine Neoplasms Version 1.2013. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#uterine.
3. Cheng H, Liu P, Zhang F, et al: A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 is highly responsive to mTOR inhibition. Cancer Res 74: 15-23, 2014.
4. Daniilidou K, Frangou-Plemenou M, Grammatikakis J, Grigoriou O, Vitoratos N and Kondi-Pafiti A: Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. J BUON 18: 195-201, 2013.
5. Patsner B and Yim GW: Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: the Asian experience 2000 to 2012. Obstet Gynecol Sci 56: 281-288, 2013.
6. Niwa H: Molecular mechanism to maintain stem cell renewal of ES cells. Cell Struct Funct 26: 137-148, 2001.
7. Niwa H, Miyazaki J and Smith AG: Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24: 372-376, 2000.
8. Pesce M and Scholer HR: Oct-4: control of totipotency and germline determination. Mol Reprod Dev 55: 452-457, 2000.
9. Pesce M and Scholer HR: Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 19: 271-278, 2001.
10. Pan GJ, Chang ZY, Schöler HR and Pei D: Stem cell pluripotency and transcription factor Oct4. Cell Res 12: 321-329, 2002.
11. Yu J, Vodyanik MA, Smuga-Otto K, et al: Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920, 2007.
12. Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006.
13. Wang YD, Cai N, Wu XL, Cao HZ , Xie LL and Zheng PS: OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis 4: e760, 2013.
14. Monk M and Holding C: Human embryonic genes re-expressed in cancer cells. Oncogene 20: 8085-8091, 2001.
15. Suo G, Han J, Wang X, et al: Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun 337: 1047-1051, 2005.
16. Huang Y, Jin H, Liu Y, et al: FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocr Relat Cancer 18: 13-26, 2010.
17. Wu Y, Liu S, Xin H, et al: Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer 117: 3989-3998, 2011.
18. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
19. Xu N, Papagiannakopoulos T, Pan G, Thomson JA and Kosik KS: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137: 647-658, 2009.
20. Hu J, Guo H, Li H, et al: MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4. PLoS One 7: e45965 2012.
21. Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146: 353-358, 2011.
22. Petrov DA and Hartl DL: Pseudogene evolution and natural selection for a compact genome. J Hered 91: 221-227, 2000.
23. Hirotsune S, Yoshida N, Chen A, et al: An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene. Nature 423: 91-96, 2003.
24. Korneev SA, Park JH and O'Shea M: Neuronal expression of neural nitric oxide synthase (nNOS) protein is suppressed by an antisense RNA transcribed from an NOS pseudogene. J Neurosci 19: 7711-7720, 1999.
25. Harrison PM, Zheng D, Zhang Z, Carriero N and Gerstein M: Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein?coding ability. Nucleic Acids Res 33: 2374-2383, 2005.
26. Han YJ, Ma SF, Yourek G, Park YD and Garcia JG: A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J 25: 2305-2312, 2011.
27. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ and Pandolfi PP: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465: 1033-1038, 2010.
28. Pain D, Chirn GW, Strassel C and Kemp DM: Multiple retropseudogenes from pluripotent cell-specific gene expression indicates a potential signature for novel gene identification. J Biol Chem 280: 6265-6268, 2005.
29. Zhang S, Wu Y, Feng D, et al: miR-145 inhibits lung adenocarcinoma stem cells proliferation by targeting OCT4 gene. Zhongguo Fei Ai Za Zhi 14: 317-322, 2011 (In Chinese).
30. Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY and Cheung AN: Dysregulated stemness-related genes in gynecological malignancies. Histol Histopathol 27: 1121-1130, 2012.
31. Zhou X, Zhou YP, Huang GR, et al: Expression of the stem cell marker, Nanog, in human endometrial adenocarcinoma. Int J Gynecol Pathol 30: 262-270, 2011.
32. Karoubi G, Gugger M, Schmid R and Dutly A: OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 8: 393-397, 2009.
33. Huang PZ, Lu CL, Li BK, et al: OCT4 expression in hepatocellular carcinoma and its clinical significance. Chin J Cancer 29: 111-116, 2010 (In Chinese).
34. Ezeh UI, Turek PJ, Reijo RA and Clark AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-2265, 2005.
35. Xu K, Zhu Z and Zeng F: Expression and significance of Oct4 in bladder cancer. J Huazhong Univ Sci Technolog Med Sci 27: 675-677, 2007.
36. Wang XQ, Ongkeko WM, Chen L, et al: Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 52: 528-539, 2010.
37. Zhang Z, Zhu Y, Lai Y, et al: Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. Int J Oncol 43: 1194-1204, 2013.
38. Li C, Yan Y, Ji W, et al: OCT4 positively regulates survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma. PLoS One 7: e49693, 2012.
39. Dai X, Ge J, Wang X, Qian X, Zhang C and Li X: OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol Rep 29: 155-160, 2013.
40. Pei D: Regulation of pluripotency and reprogramming by transcription factors. J Biol Chem 284: 3365-3369, 2009.
41. Slaby O, Svoboda M, Fabian P, et al: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402, 2007.
42. Tam OH, Aravin AA, Stein P, et al: Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 453: 534-538, 2008.
43. Ebert MS, Neilson JR and Sharp PA: MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721-726, 2007.
44. Wang L, Guo ZY, Zhang R, Xin B, Chen R, Zhao J, Wang T, Wen WH, Jia LT, Yao LB and Yang AG: Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis 34: 1773-1781, 2013.
45. Hu T, Liu S, Breiter DR, Wang F, Tang Y and Sun S: Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 68: 6533-6540, 2008.